Skip to main content
SpringerLink
Log in

Immunotherapy in Renal Cell Carcinoma

  • Chapter
  • First Online:
Advances in Tumor Immunology and Immunotherapy

Part of the book series: Current Cancer Research ((CUCR))

  • 2427 Accesses

Abstract

Renal cell carcinoma (RCC) is a chemotherapy-resistant disease, and current molecularly targeted therapies offer limited clinical benefit but no cures. The observation that RCC is immunogenic led to immune-based strategies for the treatment of this disease. Immunotherapy with high-dose IL-2 can induce long-term, complete responses in a small percentage of patients. IFN has been used as an immune intervention as well but with much less success than IL-2. Currently IFN is used only in combination with the anti-VEGF monoclonal antibody bevacizumab. Further investigation of novel immune interventions in RCC is ongoing with promising results. Dendritic cell vaccines have been tested in single-arm clinical trials suggesting improved survival when added to standard anti-angiogenic therapy. Monoclonal antibodies against PD-1 and PD-L1, novel immune targets, have shown promising response in phase I trials. Peptide vaccines have shown efficacy in phase II trials as well. Phase III trials to test these immune interventions are currently ongoing and have the potential to bring new, effective treatment options for patients with advanced RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr/factsheets/populations/factsheet.asp (2008) Accessed Aug 2012.

  2. American Cancer Society. Cancer facts and figures 2012. Atlanta: American cancer society; 2012.

    Google Scholar 

  3. Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol. 2009;182(3):854–9.

    PubMed  Google Scholar 

  4. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.

    PubMed  CAS  Google Scholar 

  5. Elhilali MM, Gleave M, Fradet Y, Davis I, Venner P, Saad F, et al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. the Canadian Urologic Oncology Group. BJU Int. 2000;86(6):613–8.

    PubMed  CAS  Google Scholar 

  6. Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol. 1993;150(2 Pt 1):463–6.

    PubMed  CAS  Google Scholar 

  7. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889–97.

    PubMed  CAS  Google Scholar 

  8. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17(9):2859–67.

    PubMed  CAS  Google Scholar 

  9. Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs. 2011;71(9):1179–91.

    PubMed  CAS  Google Scholar 

  10. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25(4):835–52.

    PubMed  Google Scholar 

  11. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144–50.

    PubMed  CAS  Google Scholar 

  12. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.

    PubMed  CAS  Google Scholar 

  13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    PubMed  CAS  Google Scholar 

  14. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.

    PubMed  CAS  Google Scholar 

  15. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9.

    PubMed  CAS  Google Scholar 

  16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.

    PubMed  CAS  Google Scholar 

  17. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.

    PubMed  CAS  Google Scholar 

  18. Gordon J, MacLean LD. A lymphocyte-stimulating factor produced in vitro. Nature. 1965;208(5012):795–6.

    PubMed  CAS  Google Scholar 

  19. Sykora KW, Kolitz J, Szabo P, Grzeschik KH, Moore MA, Mertelsmann R. Human interleukin 2 gene is located on chromosome 4. Cancer Invest. 1984;2(4):261–5.

    PubMed  CAS  Google Scholar 

  20. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983;302(5906):305–10.

    PubMed  CAS  Google Scholar 

  21. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med. 1990;171(5):1509–26.

    PubMed  CAS  Google Scholar 

  22. Baker PE, Gillis S, Smith KA. Monoclonal cytolytic T-cell lines. J Exp Med. 1979;149(1):273–8.

    PubMed  CAS  Google Scholar 

  23. Gullberg M, Smith KA. Regulation of T cell autocrine growth. T4+ cells become refractory to interleukin 2. J Exp Med. 1986;163(2):270–84.

    PubMed  CAS  Google Scholar 

  24. Hersey P, Bindon C, Edwards A, Murray E, Phillips G, McCarthy WH. Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2. Int J Cancer. 1981;28(6):695–703.

    PubMed  CAS  Google Scholar 

  25. Kanar MC, Thiele DL, Ostensen M, Lipsky PE. Regulation of human natural killer (NK) cell function: Induction of killing of an NK-resistant renal carcinoma cell line. J Clin Immunol. 1988;8(1):69–79.

    PubMed  CAS  Google Scholar 

  26. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161(5):1169–88.

    PubMed  CAS  Google Scholar 

  27. Salup RR, Back TC, Wiltrout RH. Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy. J Immunol. 1987;138(2):641–7.

    PubMed  CAS  Google Scholar 

  28. Salup RR, Wiltrout RH. Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes. Cancer Res. 1986;46(7):3358–63.

    PubMed  CAS  Google Scholar 

  29. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.

    PubMed  CAS  Google Scholar 

  30. Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997;3 Suppl 1:S92–7.

    PubMed  Google Scholar 

  31. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.

    PubMed  CAS  Google Scholar 

  32. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am. 1997;3 Suppl 1:S70–2.

    PubMed  Google Scholar 

  33. van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res. 2007;13(7):2100–8.

    PubMed  Google Scholar 

  34. von der Maase H, Geertsen P, Thatcher N, Jasmin C, Mercatello A, Fossa SD, et al. Recombinant interleukin-2 in metastatic renal cell carcinoma–a European multicentre phase II study. Eur J Cancer. 1991;27(12):1583–9.

    PubMed  Google Scholar 

  35. Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am. 2000;6 Suppl 1:S93–8.

    PubMed  Google Scholar 

  36. Vlasveld LT, Horenblas S, Hekman A, Hilton AM, Dubbelman AC, Melief CJ, et al. Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. Ann Oncol. 1994;5(2):179–81.

    PubMed  CAS  Google Scholar 

  37. Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994;12(8):1572–6.

    PubMed  CAS  Google Scholar 

  38. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial. J Clin Oncol. 2003;21(16):3133–40.

    PubMed  CAS  Google Scholar 

  39. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet. 2010;375(9715):641–8.

    PubMed  CAS  Google Scholar 

  40. Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26(2):202–9.

    PubMed  CAS  Google Scholar 

  41. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999;17(8):2521–9.

    PubMed  CAS  Google Scholar 

  42. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer. 1995;76(5):824–32.

    PubMed  CAS  Google Scholar 

  43. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995;154(1):35–40.

    PubMed  CAS  Google Scholar 

  44. Herrmann E, Brinkmann OA, Bode ME, Bierer S, Kopke T, Bogemann M, et al. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil. Eur Urol. 2007;51(6):1625,31. discussion 1631-2.

    Google Scholar 

  45. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28(5):488–95.

    PubMed  CAS  Google Scholar 

  46. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11(10):3714–21.

    PubMed  CAS  Google Scholar 

  47. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009;27(16):2645–52.

    PubMed  CAS  Google Scholar 

  48. de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, et al. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol. 2009;182(2):728–34.

    PubMed  Google Scholar 

  49. McDermott DF. The high-dose aldesleukin (HD IL-2) “SELECT” trial in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28 Suppl 15:4514.

    Google Scholar 

  50. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825–30.

    PubMed  CAS  Google Scholar 

  51. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127–32.

    PubMed  CAS  Google Scholar 

  52. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am. 1997;3 Suppl 1:S79–84.

    PubMed  Google Scholar 

  53. Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol. 1992;10(2):275–81.

    PubMed  CAS  Google Scholar 

  54. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–92.

    PubMed  CAS  Google Scholar 

  55. Negrier S, Perol D, Ravaud A, Bay JO, Oudard S, Chabaud S, et al. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. Clin Cancer Res. 2008;14(18):5907–12.

    PubMed  CAS  Google Scholar 

  56. Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a european multicentre study. Eur J Cancer Clin Oncol. 1989;25 Suppl 3:S21–8.

    PubMed  Google Scholar 

  57. Aldesleukin prescribing information. United States: U.S Department of Health & Human Services [updated 03/08/2010]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080733.htm (2010). Accessed 23 Aug 2012.

  58. NAGANO Y, KOJIMA Y. Inhibition of vaccinia infection by a liquid factor in tissues infected by homologous virus. C R Seances Soc Biol Fil. 1958;152(11):1627–9.

    PubMed  CAS  Google Scholar 

  59. Isaacs A, Lindenmann J. Virus interference I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258–67.

    PubMed  CAS  Google Scholar 

  60. Knight Jr E, Hunkapiller MW, Korant BD, Hardy RW, Hood LE. Human fibroblast interferon: amino acid analysis and amino terminal amino acid sequence. Science. 1980;207(4430):525–6.

    PubMed  CAS  Google Scholar 

  61. Derynck R, Content J, DeClercq E, Volckaert G, Tavernier J, Devos R, et al. Isolation and structure of a human fibroblast interferon gene. Nature. 1980;285(5766):542–7.

    PubMed  CAS  Google Scholar 

  62. Owerbach D, Rutter WJ, Shows TB, Gray P, Goeddel DV, Lawn RM. Leukocyte and fibroblast interferon genes are located on human chromosome 9. Proc Natl Acad Sci U S A. 1981;78(5):3123–7.

    PubMed  CAS  Google Scholar 

  63. Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung HF, Pestka S. Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol. 1982;67(1):160–7.

    PubMed  CAS  Google Scholar 

  64. Herberman RR, Ortaldo JR, Bonnard GD. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature. 1979;277(5693):221–3.

    PubMed  CAS  Google Scholar 

  65. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005;202(2):323–35.

    PubMed  CAS  Google Scholar 

  66. Fidler IJ. Regulation of neoplastic angiogenesis. J Natl Cancer Inst Monogr. 2001;28:10–4.

    PubMed  Google Scholar 

  67. Avnet S, Cenni E, Perut F, Granchi D, Brandi ML, Giunti A, et al. Interferon-alpha inhibits in vitro osteoclast differentiation and renal cell carcinoma-induced angiogenesis. Int J Oncol. 2007;30(2):469–76.

    PubMed  CAS  Google Scholar 

  68. Kosmidis PA, Baxevanis CN, Tsavaris N, Papanastasiou M, Anastasopoulos E, Bacoyiannis C, et al. The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b. J Clin Oncol. 1992;10(7):1153–7.

    PubMed  CAS  Google Scholar 

  69. Muss HB, Costanzi JJ, Leavitt R, Williams RD, Kempf RA, Pollard R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol. 1987;5(2):286–91.

    PubMed  CAS  Google Scholar 

  70. De Mulder PH, Oosterhof G, Bouffioux C, van Oosterom AT, Vermeylen K, Sylvester R. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer. 1995;71(2):371–5.

    PubMed  Google Scholar 

  71. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137,2143.

    Google Scholar 

  72. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003;21(7):1214–22.

    PubMed  CAS  Google Scholar 

  73. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.

    PubMed  CAS  Google Scholar 

  74. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.

    PubMed  CAS  Google Scholar 

  75. Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T, Toma H, et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol. 2007;25(19):2785–91.

    PubMed  CAS  Google Scholar 

  76. Kobayashi M, Suzuki K, Yashi M, Yuzawa M, Takayashiki N, Morita T. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res. 2007;27(2):1137–41.

    PubMed  CAS  Google Scholar 

  77. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–96.

    PubMed  CAS  Google Scholar 

  78. Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, et al. Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005;23(18):4172–8.

    PubMed  CAS  Google Scholar 

  79. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18(16):2972–80.

    PubMed  CAS  Google Scholar 

  80. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–4.

    PubMed  CAS  Google Scholar 

  81. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1(12):1297–302.

    PubMed  CAS  Google Scholar 

  82. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res. 1998;4(3):585–93.

    PubMed  CAS  Google Scholar 

  83. Thurnher M, Radmayr C, Ramoner R, Ebner S, Bock G, Klocker H, et al. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer. 1996;68(1):1–7.

    PubMed  CAS  Google Scholar 

  84. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3(5):558–61.

    PubMed  CAS  Google Scholar 

  85. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo Jr LD. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 1996;183(1):283–7.

    PubMed  CAS  Google Scholar 

  86. Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol. 2002;104(1):14–20.

    PubMed  CAS  Google Scholar 

  87. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth Jr RJ. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res. 2001;61(2):641–6.

    PubMed  CAS  Google Scholar 

  88. Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, Trebeden-Negre H, et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol. 2009;35(3):569–81.

    PubMed  CAS  Google Scholar 

  89. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007;30(7):749–61.

    PubMed  Google Scholar 

  90. Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol. 2007;125(3):257–67.

    PubMed  CAS  Google Scholar 

  91. Berntsen A, Trepiakas R, Wenandy L, Geertsen PF. thor Straten P, Andersen MH, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother. 2008;31(8):771–80.

    PubMed  CAS  Google Scholar 

  92. Figlin RA. Phase II, study combining personalized dendritic cell -based therapy AGS 003, with sunitinib in metastatic renal cell carcinoma. J Clin Oncol. 2012;30 Suppl 4:348.

    Google Scholar 

  93. Ridolfi R, Riccobon A. Comparison between immature and mature dendritic cells in a vaccination trial. J Clin Oncol. 2004;22(14S):2562.

    Google Scholar 

  94. Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, et al. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with aldesleukin (interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res. 2009;15(15):4986–92.

    PubMed  CAS  Google Scholar 

  95. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med. 1992;176(6):1595–604.

    PubMed  CAS  Google Scholar 

  96. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 1992;257(5071):792–5.

    PubMed  CAS  Google Scholar 

  97. Schwartz RH. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71(7):1065–8.

    PubMed  CAS  Google Scholar 

  98. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.

    PubMed  CAS  Google Scholar 

  99. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    PubMed  CAS  Google Scholar 

  100. Rini BI, Stein M, Shannon P, Eddy S, Tyler A, Stephenson Jr JJ, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;117(4):758–67.

    PubMed  CAS  Google Scholar 

  101. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23(25):6043–53.

    PubMed  CAS  Google Scholar 

  102. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–95.

    PubMed  CAS  Google Scholar 

  103. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.

    PubMed  CAS  Google Scholar 

  104. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.

    PubMed  CAS  Google Scholar 

  105. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;119(2):317–27.

    PubMed  CAS  Google Scholar 

  106. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007;13(2 Pt 2):709s–15.

    PubMed  CAS  Google Scholar 

  107. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.

    PubMed  CAS  Google Scholar 

  108. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

    PubMed  CAS  Google Scholar 

  109. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.

    PubMed  CAS  Google Scholar 

  110. Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 2002;62(20):5818–27.

    PubMed  CAS  Google Scholar 

  111. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012;18(8).

    Google Scholar 

  112. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006;66(11):5910–8.

    PubMed  CAS  Google Scholar 

  113. Holtl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother. 2005;54(7):663–70.

    PubMed  Google Scholar 

  114. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother. 2002;25(6):500–8.

    PubMed  CAS  Google Scholar 

  115. Marten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother. 2002;51(11–12):637–44.

    PubMed  Google Scholar 

  116. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther. 2003;14(5):483–94.

    PubMed  Google Scholar 

  117. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003;63(9):2127–33.

    PubMed  CAS  Google Scholar 

  118. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003;26(5):412–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, University of Miami Miller School of Medicine, 1475 NW 12 Avenue, Suite 3400, Miami, FL, 33136, USA

    Jennifer Cudris & Jaime R. Merchan

Authors
  1. Jennifer Cudris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaime R. Merchan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaime R. Merchan .

Editor information

Editors and Affiliations

  1. Sylvester Comprehensive Cancer Center (SCCC), University of Miami School of Medicine, Miami, Florida, USA

    Joseph D. Rosenblatt

  2. University of Miami Dept. Microbiology & Immunology, Miami, Florida, USA

    Eckhard R. Podack

  3. University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA

    Glen N. Barber

  4. Dept. Pediatrics, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA

    Augusto Ochoa

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cudris, J., Merchan, J.R. (2014). Immunotherapy in Renal Cell Carcinoma. In: Rosenblatt, J., Podack, E., Barber, G., Ochoa, A. (eds) Advances in Tumor Immunology and Immunotherapy. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8809-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8809-5_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8808-8

  • Online ISBN: 978-1-4614-8809-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation